biotech investing Cizzle Brands Corporation Announces Pricing of US$15,150,000 Public Offering and Nasdaq Listing
biotech investing Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business
biotech investing Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
biotech investing argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
biotech investing Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
biotech investing argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
biotech investing BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
biotech investing Immix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
biotech investing BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
biotech investing ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools' Microfluidics Business, Now Biomark Scientific
Ni-Co Energy Reports 4.60 Metres at 0.59% Nickel at Kremer-2; Phase-One Drilling Advances Magmatic Sulphide Exploration Model